Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Brefeldin A (BFA) (HB2949)
Description:Reversible protein transport inhibitor. Commonly used in cytokine staining. Enhances CRISPR-mediated HDR.
Purity:>98%
Clindamycin hydrochloride (HB4364)
Description:Antibiotic. Protein synthesis inhibitor
Purity:>98%
- Description:
Selective α-mannosidase I inhibitor
Doxycycline hyclate (HB4608)
Description:Broad-spectrum antibiotic. Used in inducible Tet-on/ Tet-off gene expression systems for gene editing.
Purity:>95%
Linezolid (HB4443)
Description:Inhibits protein synthesis in gram-positive bacteria. Antibiotic.
Purity:>98%
Minocycline hydrochloride (HB4617)
Description:Broad spectrum antibiotic. Potent microglial activation inhibitor. Allows formation of EPSs.
Purity:>98%